Welcome to our dedicated page for Aptevo Therapeutics SEC filings (Ticker: APVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aptevo Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology company developing immune-oncology candidates based on ADAPTIR and ADAPTIR-FLEX platforms. Its 8-K reports record clinical updates for mipletamig in acute myeloid leukemia, annual financial results, material agreements, executive and board changes, and other public-company events.
The company’s proxy and registration filings disclose shareholder voting matters, proposed charter and administrative amendments, Nasdaq share-issuance approvals, common-stock financing arrangements, and capital-structure information related to its standby equity purchase agreement. These filings also provide formal context for governance, securities issuance mechanics, and the funding disclosures associated with Aptevo’s oncology pipeline.
Aptevo Therapeutics (APVO) director reported an open‑market purchase on Form 4. The filing shows a buy of 13,513 shares of common stock at $1.49 per share on 11/10/2025 (Transaction Code: P). Following the trade, the director beneficially owns 13,514 shares, held directly.
Aptevo Therapeutics (APVO) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $7.5 million and a nine‑month net loss of $20.2 million. Operating expenses rose as R&D reached $4.0 million and G&A was $3.6 million for the quarter. A warrant down‑round adjustment recorded a $1.5 million deemed dividend, increasing loss attributable to common stockholders.
Cash and cash equivalents were $21.1 million at September 30, 2025, up from $8.7 million year‑end, driven by $32.7 million year‑to‑date financing cash inflows. The company raised $18.7 million, net in Q3 via its SEPA with Yorkville and ATM program, plus $4.1 million net after quarter‑end. Stockholders’ equity improved to $17.4 million. Year‑to‑date operating cash use was $20.4 million.
Financing capacity includes $10.0 million remaining under the SEPA; the ATM currently has no availability under Form S‑3 I.B.6 limits. Common warrants outstanding totaled 12,535,033, all exercisable. The company effected a 1‑for‑20 reverse split in May 2025. Clinical updates highlight mipletamig AML combination data with high remission rates and no CRS among evaluable frontline patients. Shares outstanding were 16,850,494 as of November 6, 2025.
Aptevo Therapeutics Inc. (APVO) filed an 8-K stating it furnished a press release announcing its financial results for the period ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes the information is being furnished under Item 2.02 and is not deemed “filed” for purposes of the Exchange Act or the Securities Act, and will not be incorporated by reference into other SEC filings except by specific reference.
Aptevo Therapeutics entered into Amendment No. 5 to its Rights Agreement, extending the definition of the “Final Expiration Date” to October 29, 2026. The Rights Agreement covers contingent rights to purchase one one‑thousandth of a share of the company’s Series A Junior Participating Preferred Stock. The change is disclosed as a material modification to security holder rights under Item 3.03.
Schedule 13G shows Bank of America Corporation reports beneficial ownership of 494,341 shares of Aptevo Therapeutics Inc. common stock, representing 15.0% of the outstanding class based on 3,287,918 shares. The holdings are reported as shared voting and shared dispositive power for 494,341 shares; no sole voting or dispositive power is claimed. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Point72 entities and Steven A. Cohen disclosed beneficial ownership of 299,944 shares of Aptevo Therapeutics Inc. common stock, representing 9.1% of the class as of the close of business on September 16, 2025. The filing states Point72 Asset Management and Point72 Capital Advisors have shared voting and dispositive power over these shares through their management of Point72 Associates, while Mr. Cohen controls those entities. The statement includes a certification that the shares were not acquired to change or influence control of the issuer. The reporting parties executed a joint filing agreement (Exhibit 99.1) and provided principal business address information.
Aptevo Therapeutics Inc. reported new clinical results from its RAINIER study. On September 16, 2025, the company announced a 100% remission rate in Cohort 3 of its Phase 1b/2 RAINIER trial. The study evaluates mipletamig, a first-in-class CD123 x CD3 bispecific antibody, combined with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are not candidates for intensive chemotherapy.
The company released these data through a press release, which is included as an exhibit to this report, highlighting the importance Aptevo places on this clinical milestone in its oncology pipeline.
Aptevo Therapeutics Inc. filed a current report describing a pipeline update. On September 4, 2025, the company issued a press release announcing expansion of its anti-cancer pipeline through the filing of two provisional patents for trispecific drug candidates, APVO452 and APVO451. These candidates are being developed for prostate cancer and multiple additional solid tumor types that the company describes as having significant unmet medical needs. The press release with more scientific and development details is included as Exhibit 99.1 to the report.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 164,300 warrants of Aptevo Therapeutics Inc. The filing amends a prior Schedule 13G and clarifies that the reported 164,300 warrants are subject to a 4.99% beneficial ownership limitation and correspond to 4.99% of Aptevo's common stock based on 3,287,918 shares outstanding as of August 11, 2025.
The amendment notes that it does not include an additional 1,345,075 warrants that are also subject to the 4.99% limitation. The reporting entity is organized in the Cayman Islands; David Feldman and Joel Arber are identified as its directors. The filing includes a certification that the securities were not acquired to influence control of the issuer.
Aptevo Therapeutics disclosed that CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of 357,842 shares of common stock, equal to 9.9% of the class. The reported position consists of shares issuable upon exercise of warrants; the filing shows 0 sole voting or dispositive power and 357,842 shared voting and dispositive power for the reporting persons.
The filing cites the company’s proxy indicating 3,224,156 shares outstanding as of June 20, 2025. Heights Capital is identified as the investment manager to CVI and may exercise voting and dispositive power over CVI’s holdings; both reporting persons disclaim beneficial ownership except for their pecuniary interest. The statement includes a certification that the securities were not acquired to change or influence control of the issuer.